El papel pronóstico del SUVmáx basal y cambio del SUVmáx en la PET/TC con18F-FDG en pacientes con cáncer de mama con ganglios positivos que reciben quimioterapia neoadyuvante

Can, C; Akdeniz, N; Kömek, H; Gündoğan, C; Urakçı, Z; Işıkdoğan, A.
Rev. esp. med. nucl. imagen mol. (Ed. impr.) ; 41(1): 3-10, ene-feb. 2022. ilus, tab
Artículo en Español | IBECS (España) | ID: ibc-205137

Documentos relacionados

  1. The prognostic role of baseline <sup>18</sup>F-FDG PET/CT SUVmax and SUVmax change in patients with node-positive breast cancer receiving neoadjuvant chemotherapy.
  2. PET/CT radiomics in breast cancer: Mind the step.
  3. Prediction of the axillary lymph-node metastatic burden of breast cancer by <sup>18</sup>F-FDG PET/CT-based radiomics.
  4. Predictive value of <sup>18</sup>F-FDG PET/CT-based radiomics model for neoadjuvant chemotherapy efficacy in breast cancer: a multi-scanner/center study with external validation.
  5. Association between FDG uptake in the right ventricular myocardium and cancer therapy-induced cardiotoxicity.
  6. Characterising <sup>18</sup>F-fluciclovine uptake in breast cancer through the use of dynamic PET/CT imaging.
  7. The Predictive Value of Early Changes in <sup>18</sup> F-Fluoroestradiol Positron Emission Tomography/Computed Tomography During Fulvestrant 500 mg Therapy in Patients with Estrogen Receptor-Positive Metastatic Breast Cancer.
  8. Novel Body Composition Predictors of Outcome in Patients With Angiosarcoma of the Breast: A Preliminary Study.
  9. PET Imaging of <sup>18</sup>F-(2 S,4 R)4-Fluoroglutamine Accumulation in Breast Cancer: From Xenografts to Patients.
  10. Intracellular hypoxia measured by <sup>18</sup>F-fluoromisonidazole positron emission tomography has prognostic impact in patients with estrogen receptor-positive breast cancer.